ADVENT On Air

The Road Ahead: Achieving Remission for Patients with Asthma

Listen Later

Join renowned pulmonologists Klaus Rabe, MD, PhD, FERS, and Ian Pavord, DM, FRCP, FERS, as they discuss on-treatment clinical remission as a goal in asthma management beyond disease control, and highlight the role of type 2 inflammatory biomarkers in optimizing patient outcomes.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.


    • Speaker disclosures:

    • Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci has received honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva. 
    • Klaus Rabe, MD, PhD has served on FDA and EMA panels for registration of drug for COPD. He has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Sanofi & Regeneron, Berlin Chemie, Novartis, GlaxoSmithKline, Insmed, CSL Behring making asthma and COPD drugs, and participated in clinical trials. He has never worked with the tobacco industry (and never will). He has no shares or proprietary interests of any kind.


      • © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

      MAT-GLB-2303834 V1 02/2024

      MAT-US-2402193 v1.0 - P Expiration Date: 02/26/2026

      ...more
      View all episodesView all episodes
      Download on the App Store
      ADVENT On AirBy ADVENT Program
      • 4.7
      • 4.7
      • 4.7
      • 4.7
      • 4.7

      4.7

      14 ratings